-
Mashup Score: 0
The FDA accepted darolutamide’s application for metastatic hormone-sensitive prostate cancer, imatinib is now in liquid form, and ribociclib, combined with an NSAI, showed significant benefit in high-risk, node-negative early-stage breast cancer. Brexu-cel demonstrated CNS remission in relapsed/refractory B-ALL, and a new vaccine shows promise in breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3November 2024 FDA Updates: Key Developments in Oncology - 2 day(s) ago
Here is a look back on all the FDA happenings from the month of November 2024.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
November 2024 was a significant month for the FDA, with numerous approvals, designations, and clinical trial advancements in the oncology space. Here is a look back on all the FDA happenings from the month: https://t.co/v1VmpNyH8K
-
-
Mashup Score: 2
Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Barbara O’Brien, MD, discussed the findings and implications from the phase 2 TBCRC049 study. #bcsm | @barbaraobrienmd @MDAndersonNews https://t.co/lejtGs0hwu https://t.co/PmkZdO0xFj
-
-
Mashup Score: 9
Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer | #blcsm @PGrivasMDPhD @fredhutch https://t.co/aPtPQbUGH5
-
-
Mashup Score: 4
Phase 1 trial findings showed that GD2-CAR T-cell therapy induced significant tumor regressions and neurological improvements in patients with H3K27M-mutant diffuse midline gliomas.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
A phase 1 clinical trial investigating the use of GD2-targeted CAR T cells in H3K27M-mutant diffuse midline gliomas yielded promising results, demonstrating the feasibility, safety, and early efficacy of this approach. https://t.co/a7uDtw9rSP
-
-
Mashup Score: 3
Oleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Oleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer. #lcsm https://t.co/NlEr7hV84E
-
-
Mashup Score: 7
Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Invikafusp alfa alone led to clinical activity in cancers with high tumor mutation burden including confirmed responses in microsatellite stable colorectal cancer, according to findings from the ongoing phase 1/2 START-001 trial. #crcsm https://t.co/fUqc7PTaRr
-
-
Mashup Score: 3
Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In an interview, Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial. #bcsm | @SCRIOncology @SarahCannonDocs https://t.co/TeXUqCjnMi https://t.co/X4zFv5R9Ey
-
-
Mashup Score: 16
Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 analysis, which identified the duration of prior CDK4/6 inhibitor (CDK4/6i) therapy as a potential surrogate marker for endocrine sensitivity, and discusses how these findings could help guide the selection of optimal candidates for elacestrant treatment.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease: A discussion with @OncBrothers and @PTarantinoMD. https://t.co/LWdcCVeXWQ
-
-
Mashup Score: 1FDA Approves Zanidatamab in HER2+ Biliary Tract Cancer - 5 day(s) ago
The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The #FDA has approved zanidatamab for patients with unresectable or metastatic HER2+ biliary tract cancer. https://t.co/y8Nb27d6OO
-
The FDA accepted darolutamide for metastatic hormone-sensitive prostate cancer, imatinib is now available in liquid form, and ribociclib + NSAI showed benefit in high-risk early-stage breast cancer. https://t.co/pihWtuXvWf